The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Treatment of patients with obstructive benign prostatic hypertrophy (BPH) with the drug Finasteride leads to a moderately improved urinary flow, symptomatic improvement and halts the natural progress of the disease
The global Benign Prostatic Hyperplasia Therapeutics market was valued at US$ 6476.6 million in 2023 and is anticipated to reach US$ 8438.6 million by 2030, witnessing a CAGR of 3.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Benign Prostatic Hyperplasia Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Benign Prostatic Hyperplasia Therapeutics.
Report Scope
The Benign Prostatic Hyperplasia Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Benign Prostatic Hyperplasia Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Benign Prostatic Hyperplasia Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
- Abbott Laboratories
- Allergan plc
- Astellas Pharma
- Boehringer Ingelheim Pharma GmbH and Co. KG
- Eli Lilly and Company
- GlaxoSmithKline plc
- Merck and Co.
- Pfizer
- Sanofi
- Teva Pharmaceutical Industries Limited
Segment by Type
- Alpha Blocker
- 5-Alpha Reductase Inhibitor
- Phosphodiesterase-5 Inhibitor
- Others
Segment by Application
- Mono Drug Therapy
- Combination Drug Therapy
By Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Netherlands)
- Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
- Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Benign Prostatic Hyperplasia Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Alpha Blocker
1.2.3 5-Alpha Reductase Inhibitor
1.2.4 Phosphodiesterase-5 Inhibitor
1.2.5 Others
1.3 Market by Application
1.3.1 Global Benign Prostatic Hyperplasia Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Mono Drug Therapy
1.3.3 Combination Drug Therapy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Benign Prostatic Hyperplasia Therapeutics Market Perspective (2019-2030)
2.2 Benign Prostatic Hyperplasia Therapeutics Growth Trends by Region
2.2.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Benign Prostatic Hyperplasia Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Benign Prostatic Hyperplasia Therapeutics Market Dynamics
2.3.1 Benign Prostatic Hyperplasia Therapeutics Industry Trends
2.3.2 Benign Prostatic Hyperplasia Therapeutics Market Drivers
2.3.3 Benign Prostatic Hyperplasia Therapeutics Market Challenges
2.3.4 Benign Prostatic Hyperplasia Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Benign Prostatic Hyperplasia Therapeutics Players by Revenue
3.1.1 Global Top Benign Prostatic Hyperplasia Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Benign Prostatic Hyperplasia Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Benign Prostatic Hyperplasia Therapeutics Revenue
3.4 Global Benign Prostatic Hyperplasia Therapeutics Market Concentration Ratio
3.4.1 Global Benign Prostatic Hyperplasia Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia Therapeutics Revenue in 2023
3.5 Benign Prostatic Hyperplasia Therapeutics Key Players Head office and Area Served
3.6 Key Players Benign Prostatic Hyperplasia Therapeutics Product Solution and Service
3.7 Date of Enter into Benign Prostatic Hyperplasia Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Benign Prostatic Hyperplasia Therapeutics Breakdown Data by Type
4.1 Global Benign Prostatic Hyperplasia Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Type (2025-2030)
5 Benign Prostatic Hyperplasia Therapeutics Breakdown Data by Application
5.1 Global Benign Prostatic Hyperplasia Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Benign Prostatic Hyperplasia Therapeutics Market Size (2019-2030)
6.2 North America Benign Prostatic Hyperplasia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2019-2024)
6.4 North America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Benign Prostatic Hyperplasia Therapeutics Market Size (2019-2030)
7.2 Europe Benign Prostatic Hyperplasia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2019-2024)
7.4 Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Benign Prostatic Hyperplasia Therapeutics Market Size (2019-2030)
9.2 Latin America Benign Prostatic Hyperplasia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Introduction
11.1.4 Abbott Laboratories Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.1.5 Abbott Laboratories Recent Development
11.2 Allergan plc
11.2.1 Allergan plc Company Detail
11.2.2 Allergan plc Business Overview
11.2.3 Allergan plc Benign Prostatic Hyperplasia Therapeutics Introduction
11.2.4 Allergan plc Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.2.5 Allergan plc Recent Development
11.3 Astellas Pharma
11.3.1 Astellas Pharma Company Detail
11.3.2 Astellas Pharma Business Overview
11.3.3 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Introduction
11.3.4 Astellas Pharma Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.3.5 Astellas Pharma Recent Development
11.4 Boehringer Ingelheim Pharma GmbH and Co. KG
11.4.1 Boehringer Ingelheim Pharma GmbH and Co. KG Company Detail
11.4.2 Boehringer Ingelheim Pharma GmbH and Co. KG Business Overview
11.4.3 Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Introduction
11.4.4 Boehringer Ingelheim Pharma GmbH and Co. KG Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.4.5 Boehringer Ingelheim Pharma GmbH and Co. KG Recent Development
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Company Detail
11.5.2 Eli Lilly and Company Business Overview
11.5.3 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Introduction
11.5.4 Eli Lilly and Company Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.5.5 Eli Lilly and Company Recent Development
11.6 GlaxoSmithKline plc
11.6.1 GlaxoSmithKline plc Company Detail
11.6.2 GlaxoSmithKline plc Business Overview
11.6.3 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Introduction
11.6.4 GlaxoSmithKline plc Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.6.5 GlaxoSmithKline plc Recent Development
11.7 Merck and Co.
11.7.1 Merck and Co. Company Detail
11.7.2 Merck and Co. Business Overview
11.7.3 Merck and Co. Benign Prostatic Hyperplasia Therapeutics Introduction
11.7.4 Merck and Co. Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.7.5 Merck and Co. Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Benign Prostatic Hyperplasia Therapeutics Introduction
11.8.4 Pfizer Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.8.5 Pfizer Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Detail
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Benign Prostatic Hyperplasia Therapeutics Introduction
11.9.4 Sanofi Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.9.5 Sanofi Recent Development
11.10 Teva Pharmaceutical Industries Limited
11.10.1 Teva Pharmaceutical Industries Limited Company Detail
11.10.2 Teva Pharmaceutical Industries Limited Business Overview
11.10.3 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Introduction
11.10.4 Teva Pharmaceutical Industries Limited Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2019-2024)
11.10.5 Teva Pharmaceutical Industries Limited Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
